Please use this identifier to cite or link to this item: http://localhost:80/xmlui/handle/123456789/976
Title: Sliding mode controller–observer pair for p53 pathway
Authors: Azam, Muhammad Rizwan
Uppal, Ali Arshad
Bhatti, Aamer Iqbal
Keywords: Medical and Health Sciences
Variable structure systems
Robust control
Medical control systems
Smooth control signal
Sliding mode controller–observer pair
Antitumour agent
Molecule based drug
Issue Date: 18-Jul-2019
Publisher: IET Nanobiotechnology
Abstract: A significant loss of p53 protein, an anti-tumour agent, is observed in early cancerous cells. Induction of small molecules based drug is by far the most prominent technique to revive and maintain wild-type p53 to the desired level. In this study, a sliding mode control (SMC) based robust non-linear technique is presented for the drug design of a control-oriented p53 model. The control input generated by conventional SMC is discontinuous; however, depending on the physical nature of the system, drug infusion needs to be continuous. Therefore, to obtain a smooth control signal, a dynamic SMC (DSMC) is designed. Moreover, the boundedness of the zero-dynamics is also proved. To make the model-based control design possible, the unknown states of the system are estimated using an equivalent control based, reduced-order sliding mode observer. The robustness of the proposed technique is assessed by introducing input disturbance and parametric uncertainty in the system. The effectiveness of the proposed control scheme is witnessed by performing in-silico trials, revealing that the sustained level of p53 can be achieved by controlled drug administration. Moreover, a comparative quantitative analysis shows that both controllers yield similar performance. However, DSMC consumes less control energy.
URI: http://142.54.178.187:9060/xmlui/handle/123456789/976
ISSN: 1751-875X
Appears in Collections:Journals

Files in This Item:
File Description SizeFormat 
keywords#keywords.htm133 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.